ERBB2 and breast cancer: In the ex vivo assay using freshly isolated human breast cancer tissues of three subtypes such as ER+PR+HER2-, ER+PR-HER2-, and ER-PR+, HER2+, CMLym-Dor significantly diminished the fragment size in 4 days (Supplementary Fig. 3).